Home / Market News / $PCVX

$PCVX news and market catalysts

The 14 most recent market catalysts affecting $PCVX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

14 catalysts 6 high impact 5 bullish 2 bearish Biotechnology
Nov 4, 2026 Corporate Catalyst Neutral Impact 85
Vaxcyte Reports Third Quarter 2026 Financial Results
Vaxcyte announced its Q3 2026 financial results, reporting a loss per share of $1.99, which was better than the consensus estimate of $2.12. Crucially, the company also highlighted…
Oct 12, 2026 Corporate Catalyst Neutral Impact 55
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target
Cantor Fitzgerald analyst Carter Gould reiterated an 'Overweight' rating on Vaxcyte and announced a $120 price target. This action signals continued confidence from a prominent fin…
Oct 7, 2026 Corporate Catalyst Neutral Impact 75
Reported Earlier, Vaxcyte Prices 7,412,500 Common Shares At $64.00 Each, 400,000 Pre-Funded Warrants And $500M 1.50% Convertible Notes Due 2032 In Concurrent Offerings
This headline indicates a substantial capital raise by Vaxcyte, a biotechnology company. The issuance of common shares and pre-funded warrants will lead to dilution for existing sh…
Oct 6, 2026 Corporate Catalyst Bearish Impact 85
Vaxcyte shares are trading lower after the company announced a $500 million equity offering and $500 million Convertible Notes offering.
The announcement of a $500 million equity offering and a $500 million convertible notes offering by Vaxcyte is a significant corporate catalyst. Equity offerings typically lead to …
Oct 5, 2026 Corporate Catalyst Neutral Impact 85
Vaxcyte Announces $500M Equity Offering And $500M Convertible Notes Offering
Vaxcyte's announcement of a $500 million equity offering and a $500 million convertible notes offering is a major corporate catalyst. The equity offering will lead to immediate sha…
Oct 5, 2026 Corporate Catalyst Neutral Impact 55
BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target
BTIG analyst Thomas Shrader has reaffirmed his 'Buy' rating and an $89 price target for Vaxcyte (PCVX). This action signals that the analyst's outlook on the company's fundamentals…
Oct 5, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on Vaxcyte, Raises Price Target to $122
Needham analyst Joseph Stringer raised Vaxcyte's price target from $110 to $122 while maintaining a Buy rating. This action signals increased confidence from a reputable financial …
Oct 5, 2026 Corporate Catalyst Bullish Impact 95
Vaxcyte Stock Hits New 52-Week High - Here’s Why
Vaxcyte's announcement of positive Phase 3 results for VAX-31 is a major catalyst. The vaccine candidate met all primary immunogenicity endpoints, demonstrating noninferiority to e…
Oct 5, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125
Guggenheim analyst Seamus Fernandez maintained a Buy rating on Vaxcyte and raised the price target from $116 to $125. This action signals a strengthened conviction in Vaxcyte's fut…
Oct 5, 2026 Corporate Catalyst Bullish Impact 95
Vaxcyte shares are trading. higher after the company announced topline results from the OPUS-1 pivotal adult Phase 3 trial. Vax-31 met all prespecified primary endpoints across age groups studied.
The successful topline results from Vaxcyte's OPUS-1 Phase 3 trial for Vax-31 are a major positive catalyst for the company. Meeting all prespecified primary endpoints across age g…
Oct 5, 2026 Corporate Catalyst Bullish Impact 85
Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxive
Vaxcyte reported that its VAX-31 pneumococcal conjugate vaccine candidate met all prespecified primary endpoints in the OPUS-1 pivotal adult Phase 3 trial. This includes noninferio…
Sep 25, 2026 Corporate Catalyst Neutral Impact 55
Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Target
Needham analyst Joseph Stringer reiterated a 'Buy' rating and maintained a $110 price target for Vaxcyte. This action signals continued confidence from a prominent analyst in the c…
Sep 3, 2026 Corporate Catalyst Neutral Impact 75
Vaxcyte Narrows Timing Of Topline Data From VAX-31 Adult Phase 3 OPUS-1 Trial To End Of October 2026 From Q4 2026
The narrowing of the timeline for topline data from Vaxcyte's VAX-31 adult Phase 3 OPUS-1 trial from Q4 2026 to end of October 2026 is a positive development for the company. This …
Aug 5, 2026 Corporate Catalyst Bearish Impact 75
Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate
Vaxcyte announced its Q2 earnings per share, reporting a loss of $(1.97) which significantly beat the analyst consensus estimate of $(2.22). This beat, by 11.26 percent, indicates …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.